Truist Securities Maintains Buy on Fulcrum Therapeutics, Raises Price Target to $18
Benzinga Newsdesk 11 months ago
NewsPrice TargetAnalyst Ratings
Truist Securities analyst Gregory Renza maintains Fulcrum Therapeutics (NASDAQ:FULC) with a Buy and raises the price target from $14 to $18.
Truist Securities analyst Gregory Renza maintains Fulcrum Therapeutics (NASDAQ:FULC) with a Buy and raises the price target from $14 to $18.